Loading...
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
Stock
VTVT
VTVT News & Events
-
Add to Watchlist
Trade VTVT
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Forecast
Technical
Valuation
Financials
Earnings
Should I Buy
News
VTVT News
Roth Capital Initiates Buy Rating on vTv Therapeutics with $58 Price Target
6 days ago
Benzinga
vTv Therapeutics Initiated with Buy Rating and $67 Price Target
Jan 05 2026
Benzinga
vTv Therapeutics Upgraded to Zacks Rank #2 (Buy) Reflecting Positive Earnings Outlook
Dec 24 2025
NASDAQ.COM
vTv Therapeutics Submits Phase 2 Study Protocol for Cadisegliatin in Type 2 Diabetes
Dec 18 2025
Globenewswire
vTv Therapeutics Submits Phase 2 Trial Protocol for Cadisegliatin in Type 2 Diabetes
Dec 18 2025
Newsfilter
Everything You Should Know About vTv Therapeutics (VTVT) Upgrade to Buy Rating
Nov 11 2025
NASDAQ.COM
vTv Therapeutics Files for Resale of 15.9 Million Class A Shares
Oct 03 2025
SeekingAlpha
vTv Therapeutics to Take Part in INNODIA Symposium During EASD 61st Annual Meeting
Sep 15 2025
Newsfilter
Show More News
VTVT Events
No data
VTVT Monitor News
No data
VTVT Earnings Analysis
No Data
People Also Watch